Evidence map›Paper›PMID 25335123›Full record

Trial reportPloS one2014

Recombinant erythropoietin in humans has a prolonged effect on circulating erythropoietin isoform distribution.

Niels Jacob Aachmann-Andersen, Søren Just Christensen, Kristian Lisbjerg, Peter Oturai, Anne-Kristine Meinild-Lundby, Niels-Henrik Holstein-Rathlou, Carsten Lundby, Niels Vidiendal Olsen

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 9 citations in OpenAlex.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Niels Jacob Aachmann-AndersenDepartment of Neuroscience and Pharmacology, University of Copenhagen, Copenhagen, Denmark.
Søren Just ChristensenDepartment of Neuroscience and Pharmacology, University of Copenhagen, Copenhagen, Denmark.
Kristian LisbjergDepartment of Neuroscience and Pharmacology, University of Copenhagen, Copenhagen, Denmark.
Peter OturaiClinic of Clinical Physiology, Nuclear Medicine and PET, Centre of Clinical Investigation, Rigshospitalet, Copenhagen, Denmark.
Anne-Kristine Meinild-LundbyCenter for Integrative Human Physiology (ZIHP), University of Zurich, Institute of Physiology, Zürich, Switzerland.
Niels-Henrik Holstein-RathlouDepartment of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.
Carsten LundbyCenter for Integrative Human Physiology (ZIHP), University of Zurich, Institute of Physiology, Zürich, Switzerland.
Niels Vidiendal OlsenDepartment of Neuroscience and Pharmacology, University of Copenhagen, Copenhagen, Denmark; Department of Neuroanaesthesia, The Neuroscience Centre, Rigshospitalet, Copenhagen, Denmark.
University of Copenhagen · DKRigshospitalet · DKSwiss Integrative Center for Human Health · CHUniversity of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The membrane-assisted isoform immunoassay (MAIIA) quantitates erythropoietin (EPO) isoforms as percentages of migrated isoforms (PMI). We evaluated the effect of recombinant human EPO (rhEPO) on the distribution of EPO isoforms in plasma in a randomized, placebo-controlled, double-blinded, cross-over study. 16 healthy subjects received either low-dose Epoetin beta (5000 IU on days 1, 3, 5, 7, 9, 11 and 13); high-dose Epoetin beta (30.000 IU on days 1, 2 and 3 and placebo on days 5, 7, 9, 11 and 13); or placebo on all days. PMI on days 4, 11 and 25 was determined by interaction of N-acetyl glucosamine with the glycosylation dependent desorption of EPO isoforms. At day 25, plasma-EPO in both rhEPO groups had returned to values not different from the placebo group. PMI with placebo, reflecting the endogenous EPO isoforms, averaged 82.5 (10.3) % (mean (SD)). High-dose Epoetin beta decreased PMI on days 4 and 11 to 31.0 (4.2)% (p<0.00001) and 45.2 (7.3)% (p<0.00001). Low-dose Epoetin beta decreased PMI on days 4 and 11 to 46.0 (12.8)% (p<0.00001) and 46.1 (10.4)% (p<0.00001). In both rhEPO groups, PMI on day 25 was still decreased (high-dose Epoetin beta: 72.9 (19.4)% (p=0.029); low-dose Epoetin beta: 73.1 (17.8)% (p=0.039)). In conclusion, Epoetin beta leaves a footprint in the plasma-EPO isoform pattern. MAIIA can detect changes in EPO isoform distribution up til at least three weeks after administration of Epoetin beta even though the total EPO concentration has returned to normal.

Indexed as

AdultCross-Over StudiesErythropoietinHumansMaleProtein IsoformsRecombinant Proteinsepoetin betaErythropoietinProtein IsoformsRecombinant Proteins

Identifiers

PMID25335123
PMCPMC4204994
OpenAlexW2038594811

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.